On April 18, 2023 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells, reported that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation (Press release, Phio Pharmaceuticals, APR 18, 2023, View Source [SID1234630255]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Intratumoral administration of the PD-1/CTLA-4 INTASYL improved tumor control compared to either single targeting formulation, at an identical total dose. The dual-targeting formulation was well tolerated.

"The synergistic effects of dual inhibition of PD-1 and CTLA-4 in enhancing tumor response are clinically recognized, however, a high rate of immune-related adverse events limits the utility of systemic use of this combination of products," said Dr. Mary Spellman, Phio’s Acting Chief Medical Officer. "Intratumoral administration of dual-targeting PD-1/CTLA-4 INTASYL may provide an effective treatment option, with an improved safety profile."

Presentation Details:

Poster Title:

INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4
provides synergistic antitumor efficacy in the treatment of murine colon cancer
in vivo

Session Date and Time:

Tuesday, April 18, 2023 from 1:30 PM – 5:00 PM EST